DAIICHI SANKYO, INC.

• DAIICHI SANKYO, INC. $1,660,000 In-house, the client's own filings · 7 filings
• FARRAGUT PARTNERS LLP $350,000 Outside firm · 7 filings
• TIBER CREEK GROUP $350,000 Outside firm · 7 filings
• MARSHALL & POPP, LLC $120,000 Outside firm · 4 filings

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

• H.R. 946
  ORPHAN Cures Act
  10 filings
• H.R. 2319
  Women and Lung Cancer Research and Preventive Services Act of 2025
  7 filings
• H.R. 4299
  Protecting Patient Access to Cancer and Complex Therapies Act
  6 filings
• S. 1862
  ORPHAN Cures Act
  2 filings

• 2026 $1,300,000 13 filings
• 2025 $1,180,000 12 filings

• Health Issues 21
• Medicare/Medicaid 8
• Taxation/Internal Revenue Code 7
• Pharmacy 4
• Copyright/Patent/Trademark 3
• Trade (domestic/foreign) 3

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

• HOUSE OF REPRESENTATIVES 24
• SENATE 24
• Treasury, Dept of 5
• Centers For Medicare and Medicaid Services (CMS) 3
• Food & Drug Administration (FDA) 3
• Natl Economic Council (NEC) 2
• Executive Office of the President (EOP) 1

• DAIICHI SANKYO CO., LTD. Japan named on 1 filing · highest disclosed ownership 100% · largest disclosed contribution $0

Section 7 of the LD-2: a foreign company or government that owns part of the client, pays toward the lobbying, or benefits from it. Figures are the highest single disclosure across these filings, not a sum: the same stake is re-disclosed each quarter.